Pune: Serum Institute of India’s (SII) phase 2 trial of Oxford’s COVID-19 vaccine candidate is set to commence on Tuesday.
The determination of safety and immunogenicity of “Covishield” on healthy Indian adults will start at Bharati Vidyapeeth Medical College and Hospital here.
SII has collaborated with AstraZeneca, a British-Swedish pharma company, for manufacturing of the University of Oxford-developed COVID-19 vaccine candidate.
“We have got all approvals from the Central Drugs Standard Control Organisation (CDSCO). We are going to start the human clinical trial process at the Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital from August 25.
“We are sure that in line with the philosophy of our group, we are going to make available a world class Covid-19 vaccine for people of our country and make our country ‘AatmaNirbhar’,” SSI’s additional director, Government and Regulatory Affairs, Prakash Kumar Singh was quoted as saying by news agency PTI.
Comments are closed.